Cargando…

P1022: OUTCOMES IN MYELOPROLIFERATIVE NEOPLASM PATIENTS WITH OR WITHOUT PRIOR HISTORY OF CANCER: A POPULATION-BASED STUDY FROM ONTARIO

Detalles Bibliográficos
Autores principales:	England, J. T., Bankar, A., Chan, W. C., Liu, N., Cheung, M. C., Gupta, V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430346/ http://dx.doi.org/10.1097/01.HS9.0000846956.81764.f3

Ejemplares similares

P1008: ASSOCIATION BETWEEN FRAILTY AND CLINICAL OUTCOMES IN MYELOPROLIFERATIVE NEOPLAMS: A POPULATION-BASED STUDY FROM ONTARIO, CANADA
por: Bankar, A., et al.
Publicado: (2022)

Prevalence of frailty and its association with clinical outcomes in myeloproliferative neoplasms: a population-based study
por: Bankar, Aniket, et al.
Publicado: (2023)

P1020: SCREENING FOR PORTAL HYPERTENSION IN PATIENTS WITH PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Davidson, M., et al.
Publicado: (2022)

P1026: COMPARATIVE GENOMIC PROFILING OF MYELOPROLIFERATIVE NEOPLASMS PRESENTING WITH AND WITHOUT SPLANCHNIC VEIN THROMBOSIS
por: Garrote, M., et al.
Publicado: (2022)

P984: MUTATIONAL PATTERNS IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)
por: Casetti, I. C., et al.
Publicado: (2022)

P998: REGULATION OF BCL-X SPLICING BY SRC KINASES INHIBITORS IN MYELOPROLIFERATIVE NEOPLASMS
por: Petiti, J., et al.
Publicado: (2022)

P1051: CLINICAL CHARACTERISTICS OF PULMONARY EMBOLISM IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS
por: Krecak, Ivan, et al.
Publicado: (2023)

P1071: IMPACT OF ACETYLSALICYLIC ACID DOSAGE ON INCIDENCE OF THROMBOSIS AND MORTALITY IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS.
por: Wild, A., et al.
Publicado: (2022)

P1705: PATIENT-REPORTED OUTCOMES IN MYELOPROLIFERATIVE NEOPLASMS IN CLINICAL TRIALS: A SYSTEMATIC REVIEW
por: Oliva, E. N., et al.
Publicado: (2022)

P1001: MODULATION OF MUTANT CALRETICULIN-DRIVEN ONCOGENESIS IN MYELOPROLIFERATIVE NEOPLASMS BY CLASSICAL HLA GENES
por: Shivarov, Velizar, et al.
Publicado: (2023)

P1046: SEVERE COMPLICATIONS IN JAK2 V617F POSITIVE PEDIATRIC PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
por: Novak, W., et al.
Publicado: (2022)

1022. Impact of Hospitalization on Antiretroviral Therapy for People Living with HIV
por: Ladak, Amber, et al.
Publicado: (2020)

P1050: NEXT GENERATION SEQUECING CONTRIBUTES TO DEFINE PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASM CLINICAL PHENOTYPE
por: Leone, Aldo, et al.
Publicado: (2023)

P1031: LOW-DOSE DOACS IN VERY HIGH-RISK MYELOPROLIFERATIVE NEOPLASMS: LESS BLEEDING BUT MORE ARTERIAL THROMBOTIC EVENTS
por: Herbreteau, L., et al.
Publicado: (2022)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

P1002: ANTI-FIBROTIC ACTIVITY OF BMP2 IN BONE MARROW-DERIVED MESENCHYMAL STROMAL CELLS OF MYELOPROLIFERATIVE NEOPLASMS
por: Subotički, T., et al.
Publicado: (2022)

P1724: QUALITY OF LIFE AND UNMET NEEDS AMONG PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASM PATIENTS: RESULTS OF THE NATIONWIDE SURVEY
por: Ionova, T., et al.
Publicado: (2022)

P993: INCREASED STAT5B LEVELS IN MYELOPROLIFERATIVE NEOPLASMS LEAD TO ENHANCED MEGAKARYOCYTIC DIFFERENTIATION CORRELATING WITH THROMBOSIS
por: Ploderer, Marie, et al.
Publicado: (2023)

P986: COMBINATION JAK1/2 AND CDK8/19 INHIBITION DEMONSTRATES ENHANCED EFFICACY IN MYELOPROLIFERATIVE NEOPLASMS
por: Zaroogian, Zachary, et al.
Publicado: (2023)

P1013: CBL MUTATION MAY BE ASSOCIATED WITH THE ONSET OF MYELOPROLIFERATIVE NEOPLASMS WITH MICROVASCULAR DISORDERS: A SINGLE-CENTRE EXPERIENCE
por: Micucci, Giorgia, et al.
Publicado: (2023)

P1053: NEUTROPHIL-TO-LYMPHOCYTE AND PLATELET-TO-LYMPHOCYTE RATIO AS NOVEL PROGNOSTIC BIOMARKES IN BCR-ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Cvetkovic, Mirjana, et al.
Publicado: (2023)

Risk of Thrombosis in Myeloproliferative Neoplasms after Sars-Cov-2 Vaccination
por: Borsani, Oscar, et al.
Publicado: (2022)

P1004: EFFECT AND MOLECULAR MECHANISM OF TQ05105, A NOVEL SMALL MOLECULE INHIBITOR OF JAK2 IN MYELOPROLIFERATIVE NEOPLASM
por: Zhang, W., et al.
Publicado: (2022)

P995: INDEED: A DEEP LEARNING MODEL FOR DIAGNOSIS AND SUBTYPES DIFFERENTIATION OF MYELOPROLIFERATIVE NEOPLASM BASED ON INTELLIGENCE NEURAL NETWORK
por: Wang, Rong, et al.
Publicado: (2023)

p53 as a target in myeloproliferative neoplasms
por: Lu, Min, et al.
Publicado: (2012)

Epigenetics in Myeloproliferative Neoplasms
por: McPherson, Suzanne, et al.
Publicado: (2017)

Aetiology of Myeloproliferative Neoplasms
por: McMullin, Mary Frances, et al.
Publicado: (2020)

The microenvironment in myeloproliferative neoplasm
por: Méndez-Ferrer, Simón, et al.
Publicado: (2018)

Spleen in myeloproliferative neoplasms
por: Barosi, Giovanni
Publicado: (2018)

Epigenetics in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2023)

Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
por: Person, Fermin, et al.
Publicado: (2021)

P1064: CIRCULATING CYTOKINE LEVELS IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS – PROFILE AND CLINICAL CORRELATIONS – A SINGLE CENTER STUDY
por: Tsvetkova, G., et al.
Publicado: (2022)

P992: OUTCOMES OF GLOBAL COAGULATION ASSAYS IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS WITH RESPECT TO THEIR CLINICAL AND GENETIC DETERMINANTS OF CLONAL EVOLUTION
por: Lucchesi, A., et al.
Publicado: (2022)

P1035: RING SIDEROBLASTS <15% WAS AN INDEPENDENT RISK FACTOR FOR MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM WITH SF3B1 MUTATION AND THROMBOCYTOSIS
por: LI, Fuhui, et al.
Publicado: (2023)

P988: MUTANT CALRETICULIN AND JAK2V617F DRIVER MUTATIONS INDUCE DISTINCT MITOTIC DEFECTS IN MYELOPROLIFERATIVE NEOPLASMS
por: Holl, Kristin, et al.
Publicado: (2023)

P1066: OUTCOMES OF COVID-19 IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS - AN OBSERVATIONAL COHORT STUDY FROM A LARGE ACADEMIC CANCER CENTER IN THE UNITED STATES
por: Venugopal, S., et al.
Publicado: (2022)

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival
por: Abdelmagid, Maymona G., et al.
Publicado: (2023)

Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
por: Barbui, Tiziano, et al.
Publicado: (2022)

Targeting SHP2 phosphatase in Myeloproliferative Neoplasms
por: Mali, Raghuveer Singh, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_a3c8agjlq96ltb0pnkr82m4dnb